Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BioNexus Gene Lab (BGLC) Shares Outstanding (Diluted Average) (2023 - 2025)

BioNexus Gene Lab's Shares Outstanding (Diluted Average) history spans 3 years, with the latest figure at $1.8 million for Q3 2025.

  • For Q3 2025, Shares Outstanding (Diluted Average) rose 1.12% year-over-year to $1.8 million; the TTM value through Sep 2025 reached $1.8 million, up 1.12%, while the annual FY2024 figure was $17.8 million, 12.24% up from the prior year.
  • Shares Outstanding (Diluted Average) for Q3 2025 was $1.8 million at BioNexus Gene Lab, roughly flat from $1.8 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $18.0 million in Q1 2025 and bottomed at $1.8 million in Q2 2024.
  • The 3-year median for Shares Outstanding (Diluted Average) is $8.8 million (2023), against an average of $9.6 million.
  • The largest annual shift saw Shares Outstanding (Diluted Average) grew 12.24% in 2024 before it rose 1.12% in 2025.
  • A 3-year view of Shares Outstanding (Diluted Average) shows it stood at $15.9 million in 2023, then increased by 12.24% to $17.8 million in 2024, then plummeted by 89.92% to $1.8 million in 2025.
  • Per Business Quant, the three most recent readings for BGLC's Shares Outstanding (Diluted Average) are $1.8 million (Q3 2025), $1.8 million (Q2 2025), and $18.0 million (Q1 2025).